Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis

L J W Canham, A Manara, J Fawcett, M Rolinski, A Mortimer, K E A Inglis, D A Cottrell

Research output: Contribution to journalArticle (Academic Journal)peer-review

298 Downloads (Pure)

Abstract

We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.

Original languageEnglish
Pages (from-to)38-41
Number of pages4
JournalMultiple Sclerosis and Related Disorders
Volume24
Early online date16 May 2018
DOIs
Publication statusPublished - Aug 2018

Bibliographical note

Copyright © 2018. Published by Elsevier B.V.

Fingerprint

Dive into the research topics of 'Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this